Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tharimmune ( (THAR) ) just unveiled an announcement.
Tharimmune, Inc., a publicly listed company on Nasdaq, is currently addressing a corporate governance issue related to the independence of its board of directors, as required under Nasdaq listing rules for continued inclusion on the exchange. On January 9, 2026, Tharimmune disclosed that it had received a Nasdaq notice of noncompliance with Rule 5605 after director resignations on November 6, 2025 left its board without a majority of independent directors; the company has been given a cure period extending to as late as November 6, 2026 and plans to regain compliance following a January 30, 2026 special shareholders’ meeting at which it will seek approval to elect two additional independent directors, a step that is important for maintaining its Nasdaq listing and signaling governance stability to investors.
More about Tharimmune
Average Trading Volume: 1,395,130
Technical Sentiment Signal: Buy
Current Market Cap: $114.4M
For a thorough assessment of THAR stock, go to TipRanks’ Stock Analysis page.